Lenalidomide is an immunomodulatory oral thalidomide derivate with activity in a variety of hematologic malignancies. Ferrajoli and colleagues explored lenalidomide at a starting dose of 10mg daily without interruption for relapsed and refractory CLL.
Shingles vaccine added to CDC list of vaccines for adults 60 and older; CDC recommends Tdap for postpartum women; new study suggests sequential therapy with antibiotics for H. pylori may be more effective than standard therapy; FDA Actions.
Patients with both DM and PaC could not be differentiated on the basis of tumor size or clinical stage.
A retrospective analysis of newly-diagnosed brain metastases in patients with breast cancer revealed that those with HER-2 positive disease had more favorable survival than those who were HER-2 negative. Compared to those with "triple negative" disease (median survival 4.0 months) those who had HER-2 positive disease survived 17.1 months.
In a series of 154 patients taken to surgery for isolated hepatic perfusion to treat unresectable liver metastases, the hepatic response rate was 50% and the median progression-free and overall survival was 7.4 and 24.8 months, respectively.
Even as the HIV health care community continues to make progress in improving patients' adherence to antiretroviral medication regimens, there remain some growing and stubborn obstacles to individual patients achieving the 95-plus percent adherence rate deemed optimal.
HIV/HCV coinfected patients who do not respond early on to interferon treatment will gain nothing from continued treatment, according to a study that looked at whether interferon treatment could slow liver disease progression among patients who were nonresponders to early interferon plus ribavirin treatment.1
The critical need to address mental health issues has been recognized globally and in the United States, however, significant deficiencies in access to mental health care remain for the general population and for people living with HIV/AIDS, the authors of this review article warn.
